Centrica PLC Update in respect of General Meeting 2022 (8170X)
January 07 2022 - 8:29AM
UK Regulatory
TIDMCNA
RNS Number : 8170X
Centrica PLC
07 January 2022
7 January 2022
Centrica plc
Update in respect of General Meeting 2022
On 16 December 2021, Centrica plc ("the Company"), issued a
notice convening a General Meeting of the Company ("GM") to be held
at 9:00am on 13 January 2022 at Heathrow/Marriott Hotel, Ditton
Road, Langley, Slough SL3 8PT (the "Notice of GM").
Since the Company issued the Notice of GM, the Company has been
closely monitoring the spread of the Omicron variant of COVID-19.
In view of the currently exceptionally high rates of COVID-19
("COVID") in England and growing pressure on public health services
as a result, the Company has reviewed the arrangements for the GM
with a view to protecting the health and safety of our
shareholders, employees and other potential attendees.
The health and safety of the Company's shareholders is of
paramount concern to the Directors. Therefore, in the interests of
shareholders' own safety and the safety of others, the Company
considers the most responsible approach in the current public
health circumstances is to strongly advise shareholders to appoint
the Chair of the GM as their proxy or attend the GM remotely rather
than attending the GM in person.
Shareholders' views remain very important to us and therefore
shareholders are encouraged to submit questions in advance of the
GM or attend and participate in the GM remotely via live webcast on
the Lumi platform. Shareholders can participate remotely by
following the instructions provided in the Virtual Meeting Guide
available on the Company's website which includes details for how
to submit votes and questions on the day when participating
remotely.
Instructions for submitting proxy votes are contained within the
Notice of GM. To be valid, your proxy instruction must, as
previously stated in the Notice of GM, be received by Equiniti by
no later than 9.00 am on Tuesday, 11 January 2022 or 9.00 am on
Monday 10 January in respect of shares held in FlexiShare or the
Share Incentive Plan.
Shareholders may also submit questions in advance of the meeting
until 6.30 pm on Monday 10 January 2022 via the online question
form on our website.
Any shareholders still intending to attend the GM in person are
requested to note the following health and safety measures which
will be in effect:
-- all attendees will be required to declare a negative COVID
lateral flow test taken within 24 hours of arrival at the GM before
being admitted to the GM (lateral flow tests are available free of
charge from pharmacies or can be ordered online at:
www.gov.uk/order-coronavirus-rapid-lateral-flow-tests);
-- unless exempt, all attendees will be required to wear a face
mask covering the nose and mouth at all times;
-- all attendees are requested to follow signage and layout
protocols at the venue designed for social distancing purposes;
and
-- all attendees must follow good hygiene practices at all times.
The Company reserves the right to refuse admission to the GM to
any attendees not adhering to the above measures and/or any other
reasonable requirements of the Company that are in the interests of
maintaining health and safety of attendees.
Shareholders are also reminded that, as set out in the Notice of
GM and also in the interests of minimising the public health risks
from COVID:
-- no refreshments will be provided; and
-- Directors will not be available to meet with shareholders
before or after the GM (shareholders are further informed that, in
the circumstances and for the reasons set out in this update, the
majority of Directors will not be attending the meeting in person
at the venue).
If circumstances change, including if regulations are introduced
to prohibit or further restrict public gatherings or Government
guidance changes, the Company reserves the right to take further
steps in respect of attendance at the GM. To the extent the Company
does make further changes to the arrangements for the GM, the
Company will notify shareholders via its website and (where
appropriate) via a Regulatory Information Service. Shareholders are
therefore encouraged to check Centrica's website and the latest
U.K. Government guidance before finalising any travel arrangements
to attend the GM in person.
Enquiries:
Centrica plc
Investors and Analysts
T: 01753 494900
E: ir@centrica.com
Media
T: 01784 843000
E: media@centrica.com
Ce ntr ica p l c is lis t ed on t he L o n don Stock E x c h a nge (CN A)
Regis t e r ed O ff ice: Mills t r ea m, M a i de n h e ad Ro a
d, W i n d s o r, B e r ksh i re SL4 5GD
Regis t e r ed in E n g l a nd & W a l es n u m be r: 3 0 3
3654
Leg a l E n t i ty I de n t i f i er n u m be r: E26 EDV 109 X 6
EEPBKVH76
I S I N n u m b e r: GB00 B 03 3 F 2 29
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
GMSSSWFDWEESEEF
(END) Dow Jones Newswires
January 07, 2022 08:29 ET (13:29 GMT)
Centrica (LSE:CNA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Centrica (LSE:CNA)
Historical Stock Chart
From Sep 2023 to Sep 2024